Tag:
Elusys Therapeutics
Latest Headlines
Latest Headlines
BARDA continues support of pre- and post-exposure Anthrax vax
Intramuscular injection of an anthrax prophylactic has sustained the attention of the U.S. Biomedical Advanced Research & Development Authority (BARDA) to the tune of $68 million. New
Elusys wins $143M contract for new anthrax treatment
The Department of Health and Human Services has awarded Elusys Therapeutics a contract worth up to $143 million for the development of a new anthrax therapy dubbed Anthim. The contract, which could
